Treatment of COVID-19 with COVID-19-human immunoglobulin: A case report_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

MAO Yi ¹ ,  YU He ² , LIANG Zongan ³ , WEI Jiafu ⁴ , WU Guihui ² , LUO Haixia ¹

1. Emergency Section 2 of Public Health Clinical Center of Chengdu, Chengdu, 610061, P.R.China;
2. Department of Tuberculosis of Public Health Clinical Center of Chengdu, Chengdu, 610061, P.R.China;
3. Respiratory Department of West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
4. Department of Cardiology of West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding author：

YU He, Email: 27902682@qq.com

Keywords：

Coronavirus disease 2019 (COVID-19); COVID-19-human immunoglobulin; case report

DOI：

10.7507/1007-4848.202101061

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

At present, there has been no report in China that novel coronavirus specific immune globulin has been used to treat coronavirus disease 2019 (COVID-19). Recently, we had successfully treated one COVID-19 patient with intravenous injection of human immunoglobulin (COVID-19-IVIG). The female patient, aged 57 years, had clinical diagnosis: (1) COVID-19, common type; (2) postoperative colon cancer; (3) leukopenia; (4) low cellular immunity. 75 mL COVID-19 human immunoglobulin (Sinoptic Wuhan Blood Products Co., Ltd.) was intravenously injected twice. The patient was hospitalized for 49 days and had a good prognosis.

Citation： MAO Yi, YU He, LIANG Zongan, WEI Jiafu, WU Guihui, LUO Haixia. Treatment of COVID-19 with COVID-19-human immunoglobulin: A case report. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2021, 28(11): 1388-1392. doi: 10.7507/1007-4848.202101061 Copy

1.	Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 2020, 382(10): 929-936.
2.	Gupta R, Ghosh A, Singh AK, et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr, 2020, 14(3): 211-212.
3.	Arabi YM, Asiri AY, Assiri AM, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): Statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials, 2020, 21(1): 8.
4.	Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res, 2020, 177: 104762.
5.	Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 2020, 14(1): 72-73.
6.	Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol, 2020, 38(1): 1-9.
7.	Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect, 2020, 9(1): 382-385.
8.	Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: Balancing virus clearance and immunopathology. Semin Immunopathol, 2016, 38(4): 471-482.
9.	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223): 507-513.
10.	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
11.	Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798): 270-273.
12.	Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 579(7798): 265-269.
13.	Russell B, Moss C, Rigg A, et al. COVID-19 and treatment with NSAIDs and corticosteroids: Should we be limiting their use in the clinical setting? Ecancermedicalscience, 2020, 14: 1023.
14.	Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223): 473-475.
15.	Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet, 2020, 395(10225): 683-684.
16.	Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212(9): 416-420.
17.	中华医学会呼吸病学分会, 中国医师协会呼吸医师分会. 中国成人 2019 冠状病毒病的诊治与防控指南. 中华医学杂志, 2021, 101 (18): 1293-1356.
18.	陈思锋. 2019新型冠状病毒导致的致命肺渗漏的病理生理学机制和防治策略: 兼论血透的应用与依据. 中国病理生理杂志, 2020, 36(3): 562-567.
19.	Yang P, Ding Y, Xu Z, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. MedRxiv, 2020.
20.	陈成, 张小容, 鞠振宇, 等. 新型冠状病毒肺炎引发细胞因子风暴的机制及相关免疫治疗研究进展. 中华烧伤杂志, 2020, 36 (6): 471-475.
21.	Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol, 2020, 11: 827.
22.	Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease-19 (COVID-19): A European Respiratory Society living guideline. Eur Respir J, 2021, 57(4): 2100048.
23.	Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet, 2020, 395(10223): 514-523.
24.	Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med, 2020, 8(5): 475-481.
25.	孙露, 张弨. 胸腺肽类药物在新型冠状病毒肺炎应用中的思考. 临床药物治疗杂志, 2020, 18(3): 63-67.
26.	Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020, 584(7819): 120-124.
27.	Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res, 2017, 137: 82-92.
28.	Hung IFN, To KKW, Lee CK, et al. Hyperimmune Ⅳ immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest, 2013, 144(2): 464-473.
29.	Pei L, Zhang S, Huang L, et al. Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin in 1142 patients with coronavirus disease 2019: A systematic review and meta-analysis. Pol Arch Intern Med, 2020, 130(9): 726-733.
30.	Charlet R, Sendid B, Kaveri SV, et al. Intravenous immunoglobulin therapy eliminates candida albicans and maintains intestinal homeostasis in a murine model of dextran sulfate sodium-induced colitis. Int J Mol Sci, 2019, 20(6): 1473.
31.	Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci, 2020, 21(7): 2272.

1. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 2020, 382(10): 929-936.
2. Gupta R, Ghosh A, Singh AK, et al. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr, 2020, 14(3): 211-212.
3. Arabi YM, Asiri AY, Assiri AM, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): Statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials, 2020, 21(1): 8.
4. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res, 2020, 177: 104762.
5. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends, 2020, 14(1): 72-73.
6. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol, 2020, 38(1): 1-9.
7. Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect, 2020, 9(1): 382-385.
8. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: Balancing virus clearance and immunopathology. Semin Immunopathol, 2016, 38(4): 471-482.
9. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet, 2020, 395(10223): 507-513.
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395(10223): 497-506.
11. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 579(7798): 270-273.
12. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 579(7798): 265-269.
13. Russell B, Moss C, Rigg A, et al. COVID-19 and treatment with NSAIDs and corticosteroids: Should we be limiting their use in the clinical setting? Ecancermedicalscience, 2020, 14: 1023.
14. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet, 2020, 395(10223): 473-475.
15. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet, 2020, 395(10225): 683-684.
16. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 2020, 212(9): 416-420.
17. 中华医学会呼吸病学分会, 中国医师协会呼吸医师分会. 中国成人 2019 冠状病毒病的诊治与防控指南. 中华医学杂志, 2021, 101 (18): 1293-1356.
18. 陈思锋. 2019新型冠状病毒导致的致命肺渗漏的病理生理学机制和防治策略: 兼论血透的应用与依据. 中国病理生理杂志, 2020, 36(3): 562-567.
19. Yang P, Ding Y, Xu Z, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. MedRxiv, 2020.
20. 陈成, 张小容, 鞠振宇, 等. 新型冠状病毒肺炎引发细胞因子风暴的机制及相关免疫治疗研究进展. 中华烧伤杂志, 2020, 36 (6): 471-475.
21. Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol, 2020, 11: 827.
22. Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease-19 (COVID-19): A European Respiratory Society living guideline. Eur Respir J, 2021, 57(4): 2100048.
23. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet, 2020, 395(10223): 514-523.
24. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med, 2020, 8(5): 475-481.
25. 孙露, 张弨. 胸腺肽类药物在新型冠状病毒肺炎应用中的思考. 临床药物治疗杂志, 2020, 18(3): 63-67.
26. Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, 2020, 584(7819): 120-124.
27. Liu WJ, Zhao M, Liu K, et al. T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res, 2017, 137: 82-92.
28. Hung IFN, To KKW, Lee CK, et al. Hyperimmune Ⅳ immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest, 2013, 144(2): 464-473.
29. Pei L, Zhang S, Huang L, et al. Antiviral agents, glucocorticoids, antibiotics, and intravenous immunoglobulin in 1142 patients with coronavirus disease 2019: A systematic review and meta-analysis. Pol Arch Intern Med, 2020, 130(9): 726-733.
30. Charlet R, Sendid B, Kaveri SV, et al. Intravenous immunoglobulin therapy eliminates candida albicans and maintains intestinal homeostasis in a murine model of dextran sulfate sodium-induced colitis. Int J Mol Sci, 2019, 20(6): 1473.
31. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? Int J Mol Sci, 2020, 21(7): 2272.

Previous Article
Research progress of endoscopic vacuum-assisted closure therapy for esophageal fistulas
Next Article
重视腹主动脉瘤的规范化治疗

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Treatment of COVID-19 with COVID-19-human immunoglobulin: A case report

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content